Angiotensin-converting enzyme inhibitor-associated angioedema
Angiotensin-converting enzyme inhibitor-associated angioedema
复制标题
DOI：
10.1016/j.iac.2006.08.001
复制
发表时间：
2006-11-01
影响因子：
2.6
通讯作者：
Brown, Nancy J.
中科院分区：
文献类型：
--
作者：
Byrd, James Brian;Adam, Albert;Brown, Nancy J.
血管水肿，以嘴唇、面部和舌头肿胀为特征，在0.1%至6%的血管紧张素转换酶（ACE）抑制剂使用者中发生。美国黑人比白人、女性比男性、吸烟者比非吸烟者更常见。ACE抑制剂相关性血管性水肿的缓解性和复发性可以混淆临床对不良事件的认识，但也为其原因提供了线索。ACE的血管活性肽底物（如缓激肽或P物质）的缺陷降解可能通过非ACE途径参与ACE抑制剂相关血管性水肿的发病机制。
Angioedema, characterized by swelling of the lips, face, and tongue, occurs in anywhere from 0.1% to 6% of angiotensin-converting enzyme (ACE) inhibitor users. The incidence is more common in black Americans than in white Americans, in women than in men, and in smokers than in nonsmokers. The remitting and relapsing nature of ACE inhibitor-associated angioedema can confound clinical recognition of the adverse event but also provides clues to its causes. Defective degradation of vasoactive peptide substrates of ACE, such as bradykinin or substance P, may contribute via non-ACE pathways to the pathogenesis of ACE inhibitor-associated angioedema.